T
Tulin Budak-Alpdogan
Researcher at Memorial Sloan Kettering Cancer Center
Publications - 13
Citations - 397
Tulin Budak-Alpdogan is an academic researcher from Memorial Sloan Kettering Cancer Center. The author has contributed to research in topics: Medicine & Cancer research. The author has an hindex of 4, co-authored 4 publications receiving 376 citations.
Papers
More filters
Journal ArticleDOI
Novel aspects of resistance to drugs targeted to dihydrofolate reductase and thymidylate synthase.
Debabrata Banerjee,Philipp Mayer-Kuckuk,Gina M. Capiaux,Gina M. Capiaux,Tulin Budak-Alpdogan,Richard Gorlick,Joseph R. Bertino +6 more
TL;DR: The molecular mechanisms that govern translational regulation of DHFR in response to MTX as an additional resistance mechanism are studied in detail and gene copy number of the E2F-1 gene appears to be increased in a significant number of samples obtained from metastases of colorectal cancer.
Journal ArticleDOI
Chimeric receptor mRNA transfection as a tool to generate antineoplastic lymphocytes
Peter M. Rabinovich,Marina E. Komarovskaya,Stephen H. Wrzesinski,Jonathan Alderman,Tulin Budak-Alpdogan,Alexander Karpikov,Hongfen Guo,Richard A. Flavell,Nai-Kong Cheung,Sherman M. Weissman,Erkut Bahceci +10 more
TL;DR: It is demonstrated that a mixed population of cytotoxic lymphocytes, including T cells together with NK cells, can be quickly and simultaneously reprogrammed by mRNA against autologous malignancies.
Journal ArticleDOI
Retroviral transduction of a mutant dihydrofolate reductase-thymidylate synthase fusion gene into murine marrow cells confers resistance to both methotrexate and 5-fluorouracil.
Gina M. Capiaux,Tulin Budak-Alpdogan,Naoko Takebe,Naoko Takebe,Philipp Mayer-Kuckuk,Debabrata Banerjee,Frank Maley,Joseph R. Bertino +7 more
TL;DR: The fusion DHFR F/S-TS G52S fusion protein is functional and exhibits kinetic properties similar to that of the individual mutant enzymes and may be useful in the clinic to reduce myelosuppressive toxicity associated with this drug combination.
Journal ArticleDOI
Protection of hematopoietic stem cells from pemetrexed toxicity by retroviral gene transfer with a mutant dihydrofolate reductase-mutant thymidylate synthase fusion gene
Gina M. Capiaux,Gina M. Capiaux,Tulin Budak-Alpdogan,Onder Alpdogan,William Bornmann,Naoko Takebe,Naoko Takebe,Debabrata Banerjee,Debabrata Banerjee,Frank Maley,Joseph R. Bertino,Joseph R. Bertino,Joseph R. Bertino +12 more
TL;DR: Examination of the sensitivity of the DHFR F/S-TS G52S fusion protein to the multitargeted antifolate, pemetrexed, found that co-expression of mutant DHFR and TS enzymes has additive effects in conferring resistance to pemberrexed-induced toxicity.
Journal ArticleDOI
North American Blastic Plasmacytoid Dendritic Cell Neoplasm Consortium: Position on Standards of Care and Areas of Need.
Naveen Pemmaraju,Hagop M. Kantarjian,Kendra Sweet,Eunice S. Wang,Jayastu Senapati,Nathaniel R. Wilson,Marina Konopleva,Arthur E. Frankel,Vikas Gupta,Ruben A. Mesa,M. Ulrickson,Edward J. Gorak,Sumeet Bhatia,Tulin Budak-Alpdogan,James R. Mason,María Teresa García-Romero,Norma Lopez-Santiago,Gabriela Cesarman-Maus,Pankit Vachhani,Sangmin Lee,Vijaya Raj Bhatt,William Blum,Roland B. Walter,Dale L. Bixby,Ivana Gojo,Madeleine Duvic,Raajit K. Rampal,Marcos de Lima,James M. Foran,Amir T. Fathi,Aric C. Hall,Meagan A. Jacoby,Jeffrey E. Lancet,Gabriel N. Mannis,Anthony S. Stein,Alice S. Mims,David A. Rizzieri,Rebecca L. Olin,Alexander E. Perl,Gary J. Schiller,Paul J. Shami,Richard Stone,Stephen A. Strickland,Matthew J. Wieduwilt,Naval Daver,Farhad Ravandi,Sumithira Vasu,Monica L. Guzman,Gail J. Roboz,Joseph D. Khoury,Muzaffar H. Qazilbash,Phyu P. Aung,Branko Cuglievan,Yazan F. Madanat,Mohamed A. Kharfan-Dabaja,Anna B. Pawlowska,Justin Taylor,Martin S. Tallman,Prajwal Dhakal,Andrew N. Lane +59 more
TL;DR: The first-in-class agent for BPDCN, tagraxofusp, which targets CD123, was approved in December 2018 in the United States for patients with BPDC ages 2 and older as mentioned in this paper .